Satellos Bioscience Inc. (NASDAQ:MSLE) Receives Consensus Rating of “Hold” from Analysts

Satellos Bioscience Inc. (NASDAQ:MSLE) has earned a consensus rating of “Hold” from the five analysts that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have given a buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $15.50.

MSLE has been the subject of a number of recent research reports. Cantor Fitzgerald began coverage on shares of Satellos Bioscience in a research note on Wednesday, March 11th. They issued an “overweight” rating for the company. Leerink Partners began coverage on shares of Satellos Bioscience in a research report on Monday. They issued an “outperform” rating and a $20.00 price objective on the stock. Weiss Ratings assumed coverage on shares of Satellos Bioscience in a research report on Wednesday, February 11th. They set a “sell (d-)” rating for the company. HC Wainwright boosted their target price on shares of Satellos Bioscience to $11.00 and gave the stock a “buy” rating in a research note on Monday, March 30th. Finally, Wall Street Zen lowered Satellos Bioscience to a “strong sell” rating in a report on Saturday, March 14th.

Satellos Bioscience Price Performance

NASDAQ MSLE traded up $0.13 during trading hours on Monday, hitting $6.00. 8,352 shares of the company were exchanged, compared to its average volume of 67,450. The company has a market cap of $92.70 million, a price-to-earnings ratio of -3.87 and a beta of 1.37. Satellos Bioscience has a 52-week low of $4.53 and a 52-week high of $13.39.

Satellos Bioscience (NASDAQ:MSLE) last announced its quarterly earnings data on Friday, March 27th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.11).

Satellos Bioscience Company Profile

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.